Skip to main content
Erschienen in: Journal of Endocrinological Investigation 12/2018

01.12.2018 | Original Article

Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study

verfasst von: G. Lanzolla, E. Sabini, M. A. Profilo, B. Mazzi, A. Sframeli, R. Rocchi, F. Menconi, M. Leo, M. Nardi, P. Vitti, C. Marcocci, M. Marinò

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

It has been suggested that high cholesterol represents a risk factor for Graves’ orbitopathy (GO). In a recent cross-sectional study, a correlation between cholesterol and the presence of GO was found in patients with a Graves’ disease (GD) of recent onset. To confirm this observation, we conducted a retrospective investigation in consecutive patients with GD. The primary outcome was the relationship between the presence of GO and low-density lipoprotein (LDL)-cholesterol.

Methods

The design entailed the inclusion of consecutive patients with a GD of recent onset, with or without GO, who came to our observation to receive radioiodine over a period of 6 months, and a stratification aimed at having two homogeneous group of patients in terms of thyroid function. A total of 86 patients fulfilled the inclusion and evaded the exclusion criteria. All patients underwent an ophthalmological assessment and serum lipids were measured.

Results

Serum levels of LDL-cholesterol were significantly higher in patients with GO (135.3 ± 41.3 mg/dL) compared with those without GO (106.6 ± 23.9 mg/dL, P = 0.0007). In a similar manner, serum levels of total cholesterol were higher in patients with GO (211.6 ± 44.0 mg/dL) than in those without GO (176.0 ± 27.2 mg/dL, P = 0.0001). There was no relationship between GO severity and activity and cholesterol. There was no relationship between GO and high-density lipoprotein-cholesterol or triglycerides.

Conclusions

Our study confirms a relationship between the presence of GO and cholesterol in patients with GD of recent onset. Whether lowering of cholesterol ameliorates, GO remains to be established.
Literatur
1.
Zurück zum Zitat Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R (2015) Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 133:290–296CrossRef Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R (2015) Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 133:290–296CrossRef
2.
Zurück zum Zitat Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M (2018) High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a Cross-Sectional Study. Thyroid 28:386–394CrossRef Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M (2018) High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a Cross-Sectional Study. Thyroid 28:386–394CrossRef
3.
Zurück zum Zitat Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449PubMed Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449PubMed
4.
Zurück zum Zitat Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2014) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294CrossRef Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2014) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294CrossRef
5.
Zurück zum Zitat Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661–668CrossRef Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661–668CrossRef
6.
Zurück zum Zitat Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Invest 38:809–815CrossRef Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Invest 38:809–815CrossRef
7.
Zurück zum Zitat Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1990) Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 150:1098–1101CrossRef Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1990) Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 150:1098–1101CrossRef
8.
Zurück zum Zitat Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–77CrossRef Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–77CrossRef
9.
Zurück zum Zitat Watanabe N, Yoshimura NJ, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto N, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K (2015) Radioiodine-associated exacerbation of Graves’ orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100:2700–2708CrossRef Watanabe N, Yoshimura NJ, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto N, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K (2015) Radioiodine-associated exacerbation of Graves’ orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100:2700–2708CrossRef
10.
Zurück zum Zitat Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96 (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3007–3700CrossRef Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96 (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3007–3700CrossRef
11.
Zurück zum Zitat Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151CrossRef Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151CrossRef
12.
Zurück zum Zitat Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR (2016) Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. J Clin Endocrinol Metab 101:2711–2720CrossRef Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR (2016) Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. J Clin Endocrinol Metab 101:2711–2720CrossRef
13.
Zurück zum Zitat Anagnostis P, Boboridis K, Adamidou F, Kita M (2017) Natural course of mild Graves’ orbitopathy: is it a chronic remitting or a transient disease? J Endocrinol Invest 40:257–261CrossRef Anagnostis P, Boboridis K, Adamidou F, Kita M (2017) Natural course of mild Graves’ orbitopathy: is it a chronic remitting or a transient disease? J Endocrinol Invest 40:257–261CrossRef
14.
Zurück zum Zitat Bifulco M, Ciaglia E (2016) Statin reduces orbitopathy risk in patients with Graves’ disease by modulating apoptosis and autophagy activities. Endocrine 53:649–650CrossRef Bifulco M, Ciaglia E (2016) Statin reduces orbitopathy risk in patients with Graves’ disease by modulating apoptosis and autophagy activities. Endocrine 53:649–650CrossRef
15.
Zurück zum Zitat Bahn RS (2015) Current Insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778CrossRef Bahn RS (2015) Current Insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778CrossRef
16.
Zurück zum Zitat Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? J Endocrinol Invest 41:193–201CrossRef Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? J Endocrinol Invest 41:193–201CrossRef
17.
Zurück zum Zitat Goldstein JL, Brown MS (2015) A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161:161–172CrossRef Goldstein JL, Brown MS (2015) A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161:161–172CrossRef
18.
Zurück zum Zitat Covelli D, Vannucchi G, Campi I, Currò N, D’Ambrosio R, Maggioni M, Gianelli U, Beck-Peccoz P, Salvi M (2015) Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves’ orbitopathy. J Clin Endocrinol Metab 100:1731–1737CrossRef Covelli D, Vannucchi G, Campi I, Currò N, D’Ambrosio R, Maggioni M, Gianelli U, Beck-Peccoz P, Salvi M (2015) Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves’ orbitopathy. J Clin Endocrinol Metab 100:1731–1737CrossRef
19.
Zurück zum Zitat Sabini E, Sisti E, Coco B, Leo M, Ionni I, Menconi F, Profilo MA, Mazzi B, Rocchi R, Latrofa F, Vitti P, Brunetto M, Marcocci C, Marinò M (2016) Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy. J Endocrinol Invest 39:1323–1327CrossRef Sabini E, Sisti E, Coco B, Leo M, Ionni I, Menconi F, Profilo MA, Mazzi B, Rocchi R, Latrofa F, Vitti P, Brunetto M, Marcocci C, Marinò M (2016) Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy. J Endocrinol Invest 39:1323–1327CrossRef
20.
Zurück zum Zitat Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 5:9–26CrossRef Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 5:9–26CrossRef
21.
Zurück zum Zitat Stan MN, Garrity JA, Bahn RS (2012) The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 96:311–328CrossRef Stan MN, Garrity JA, Bahn RS (2012) The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 96:311–328CrossRef
22.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, Bart van der Worp H, van Dis I, Verschuren WM (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252:207–274CrossRef Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, Bart van der Worp H, van Dis I, Verschuren WM (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252:207–274CrossRef
23.
Zurück zum Zitat Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 23:161–168CrossRef Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 23:161–168CrossRef
24.
Zurück zum Zitat Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525–528CrossRef Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525–528CrossRef
25.
Zurück zum Zitat Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1658CrossRef Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1658CrossRef
26.
Zurück zum Zitat Ponziani FR, Pecere S, Gasbarrini A, Ojetti V (2015) Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol 9:1055–1067CrossRef Ponziani FR, Pecere S, Gasbarrini A, Ojetti V (2015) Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol 9:1055–1067CrossRef
27.
Zurück zum Zitat Busnelli M, Manzini S, Froio A, Vargiolu A, Cerrito MG, Smolenski RT, Giunti M, Cinti A, Zannoni A, Leone BE, Forni M, Bacci ML, Biasi GM, Giovannoni R, Lavitrano M (2013) Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury—rescue by high-dose statin treatment. PLoS One 8:e80588CrossRef Busnelli M, Manzini S, Froio A, Vargiolu A, Cerrito MG, Smolenski RT, Giunti M, Cinti A, Zannoni A, Leone BE, Forni M, Bacci ML, Biasi GM, Giovannoni R, Lavitrano M (2013) Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury—rescue by high-dose statin treatment. PLoS One 8:e80588CrossRef
Metadaten
Titel
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study
verfasst von
G. Lanzolla
E. Sabini
M. A. Profilo
B. Mazzi
A. Sframeli
R. Rocchi
F. Menconi
M. Leo
M. Nardi
P. Vitti
C. Marcocci
M. Marinò
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 12/2018
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0915-z

Weitere Artikel der Ausgabe 12/2018

Journal of Endocrinological Investigation 12/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.